Kyverna Therapeutics, Inc. KYTX Cash Flow Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| -$161.31M-26.5% | -$127.48M-111% | ||
| $1.8M-15.7% | $2.13M+25.0% | ||
| $10.08M+20.6% | $8.36M+276% | ||
| $543K— | —— | ||
| $5.11M+147% | $2.07M+47.8% | ||
| —— | $1.96M+5.7% | ||
| -$3.34M-39.2% | -$2.4M-42.9% | ||
| -$153.71M-34.5% | -$114.25M-118% | ||
| —— | $2.21M+255% | ||
| —— | —— | ||
| $24.7M— | $0— | ||
| $16.94M— | $0-100% | ||
| $808K-16.2% | $964K+23.6% | ||
| —— | —— | ||
| $141.17M— | —— | ||
| $27.47M— | —— | ||
| $415K+192% | $142K-24.1% | ||
| $6.89M-10.1% | $7.66M+582% | ||
| —— | —— | ||
| -$2.5M— | $0— | ||
| $5.11M+147% | $2.07M+47.8% | ||
| -$3.34M-39.2% | -$2.4M-42.9% | ||
| -$800K-107% | $10.91M+310% | ||
| —— | $1.5M— | ||
| —— | $0— | ||
| $2.9M+14.0% | $2.54M+47.9% | ||
| $808K-16.2% | $964K+23.6% | ||
| $144K— | —— | ||
| $475K— | —— | ||
| $98.97M— | —— | ||
| -$3.34M-39.2% | -$2.4M-42.9% | ||
| $194K— | —— | ||
| —— | —— | ||
| -$153.72M-32.0% | -$116.46M-120% | ||
| -$153.72M-32.0% | -$116.46M-120% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kyverna Therapeutics, Inc. generate?
- Kyverna Therapeutics, Inc. (KYTX) generated -$150.4M in operating cash flow over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s free cash flow?
- After $538.0K of capital expenditures, Kyverna Therapeutics, Inc.'s free cash flow was -$153.7M over the trailing twelve months, down 32.0% year over year.
- Where does Kyverna Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.